Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

Journal of Clinical Oncology

Volumn 27, Issue 21, 2009, Pages 3518-3525

  Richardson, Paul G ^a   Xie, Wanling ^a   Mitsiades, Constantine ^a   Chanan Khan, Asher A ^a   Lonial, Sagar ^a   Hassoun, Hani ^a   Avigan, David E ^a   Oaklander, Anne Louise ^a   Kuter, David J ^a   Wen, Patrick Y ^a   Kesari, Santosh ^a   Briemberg, Hannah R ^a   Schlossman, Robert L ^a   Munshi, Nikhil C ^a   Heffner, L Thompson ^a   Doss, Deborah ^a   Esseltine, Dixie Lee ^a   Weller, Edie ^a   Anderson, Kenneth C ^a   Amato, Anthony A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; ACICLOVIR; ALPHA TOCOPHEROL; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARNITINE; CORTICOSTEROID; FOLIC ACID; GABAPENTIN; GLUTAMINE; HEMOPOIETIC GROWTH FACTOR; MAGNESIUM; MOLECULAR MARKER; PYRIDOXINE; THIOCTIC ACID; VITAMIN B COMPLEX; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW BIOPSY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENOME; HERPES ZOSTER; HUMAN; HYPOTENSION; INCIDENCE; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NERVE FIBER; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PREVALENCE; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN BIOPSY; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE; DRUG POTENTIATION; DRUG RESISTANCE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYNEUROPATHIES; PROTEASE INHIBITORS; PYRAZINES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 70249146895     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.3087     Document Type: Article

References (55)

1. Richardson PG, Mitsiades C, Schlossman R, et al: New drugs for myeloma. Oncologist 12:664-689, 2007
2. Richardson PG, Hideshima T, Mitsiades C, et al: The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw 5:149-162, 2007
3. Manochakian R, Miller KC, Chanan-Khan AA: Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist 12: 978-990, 2007
4. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
5. Richardson PG, Sonneveld P, Schuster M, et al: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 110:3557-3560, 2007
6. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127: 165-172, 2004
7. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
8. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
9. Popat R, Oakervee H, Curry N, et al: Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: Updated results after long-term follow-up. Br J Haematol 141:512-516, 2008
10. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120, 2006
11. Richardson PG, Sonneveld P, Schuster MW, et al: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of dosemodification guideline. Br J Haematol 144:895-903, 2009
12. Dispenzieri A, Kyle RA: Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18:673-688, 2005
13. Plasmati R, Pastorelli F, Cavo M, et al: Neuropathy in multiple myeloma treated with thalidomide: A prospective study. Neurology 69:573-581, 2007
14. Kelly JJ Jr, Kyle RA, Miles JM, et al: The spectrum of peripheral neuropathy in myeloma. Neurology 31:24-31, 1981
15. Silverstein A, Doniger DE: Neurologic complications of myelomatosis. Arch Neurol 9:534-544, 1963
16. Walsh JC: The neuropathy of multiple myeloma. An electrophysiological and histological study. Arch Neurol 25:404-414, 1971
17. Mulligan G, Mitsiades C, Bryant B, et al: Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109:3177-3188, 2007
18. Colson K, Doss DS, Swift R, et al: Expanding role of bortezomib in multiple myeloma: Nursing implications. Cancer Nurs 31:239-249, 2008
19. Tariman JD, Love G, McCullagh E, et al: Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 12:29-36, 2008
20. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT-European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
21. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006
22. Calhoun EA, Welshman EE, Chang CH, et al: Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741-748, 2003
23. Herrmann DN, Griffin JW, Hauer P, et al: Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 53: 1634-1640, 1999
24. Periquet MI, Novak V, Collins MP, et al: Painful sensory neuropathy: Prospective evaluation using skin biopsy. Neurology 53:1641-1647, 1999
25. Wallengren J, Tegner E, Sundler F: Cutaneous sensory nerve fibers are decreased in number after peripheral and central nerve damage. J Am Acad Dermatol 46:215-217, 2002
26. England JD, Gronseth GS, Franklin G, et al: Distal symmetric polyneuropathy: A definition for clinical research-Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64: 199-207, 2005
27. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
28. Shaffer AL, Rosenwald A, Hurt EM, et al: Signatures of the immune response. Immunity 15: 375-385, 2001
29. Annunziata CM, Davis RE, Demchenko Y, et al: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007
30. Alexanian R, Dimopoulos MA, Delasalle K, et al: Primary dexamethasone treatment of multiple myeloma. Blood 80:887-890, 1992
31. Facon T, Mary JY, Pegourie B, et al: Dexamethasone-based regimens versus melphalanprednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107:1292-1298, 2006
32. Kumar S, Lacy MQ, Dispenzieri A, et al: Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 34:485-490, 2004
33. Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006
34. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
35. Rajkumar SV, Rosinol L, Hussein M, et al: Multicenter, randomized, double-blind, placebocontrolled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26:2171-2177, 2008
36. Jagannath S, Richardson PG, Sonneveld P, et al: Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21:151-157, 2007
37. Mateos MV, Hernandez JM, Hernandez MT, et al: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase I/II study. Blood 108:2165-2172, 2006
38. Kropff MH, Bisping G, Wenning D, et al: Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 29:587-590, 2005
39. Sagaster V, Ludwig H, Kaufmann H, et al: Bortezomib in relapsed multiple myeloma: Response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 21: 164-168, 2007
40. Cavo M, Patriarca F, Tacchetti P, et al: Bortezomib (Velcade)- thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood 110:30a, 2007 (suppl; abstr 73)
41. Harousseau JL, Mathiot C, Attal M, et al: Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial. J Clin Oncol 26:455s, 2008 (suppl; abstr 8505)
42. Harousseau J-L, Attal M, Leleu X, et al: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 91:1498-1505, 2006
43. Rosiñol L, Oriol A, Mateos MV, et al: Phase II pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics. J Clin Oncol 25:4452-4458, 2007
44. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma (V. 2.2009). http://www.nccn.org/ professionals/physician-gls/PDF/myeloma.pdf
45. Oakervee H, Popat R, Cavenagh JD: Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment. Leuk Lymphoma 48:1910-1921, 2007
46. Bennett CL, Angelotta C, Yarnold PR, et al: Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296: 2558-2560, 2006
47. Knight R, DeLap RJ, Zeldis JB: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079-2080, 2006
48. Richardson P, Schlossman R, Jagannath S, et al: Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79:875-882, 2004
49. Mileshkin L, Stark R, Day B, et al: Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507-4514, 2006
50. Hulin C, Facon T, Rodon P, et al: Melphalanprednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalanprednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 110:31a, 2007 (suppl; abstr 75)
51. Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360, 2004
52. Anderson KC, Jagannath S, Jakubowiak A, et al: Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol 26:465s, 2008 (suppl; abstr 8545)
53. Richardson PG, Chanan-Khan A, Lonial S, et al: Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Confirmation of the recommended dose using a novel formulation. Blood 110:353a, 2007 (suppl; abstr 1165)
54. Richardson PG, Lonial S, Jakubowiak A, et al: Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study. J Clin Oncol 26:459s, 2008 (suppl; abstr 8520)
55. Richardson PG, Jagannath S, Avigan DE, et al: Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial. Blood 108:124a, 2006 (suppl; abstr 405)